Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (TCRX) is a clinical-stage biopharmaceutical leader developing novel T cell receptor-engineered therapies for cancer treatment. This dedicated news hub provides investors and industry professionals with essential updates on the company's scientific advancements, regulatory progress, and strategic initiatives.
Access real-time information about TCRX's clinical trial developments, including updates on its liquid tumor and solid tumor therapy candidates. Stay informed about FDA designations, partnership announcements, and financial disclosures that shape the company's position in the competitive immunotherapy landscape.
Key coverage areas include breakthrough therapy designations, manufacturing innovations, preclinical data releases, and executive leadership updates. All content is curated to meet the needs of stakeholders requiring timely, accurate information about TCRX's progress in advancing TCR-T cell therapies.
Bookmark this page for centralized access to verified TScan Therapeutics announcements. Combine regular monitoring with SEC filings and earnings reports to maintain a complete perspective on the company's trajectory in precision oncology.
TScan Therapeutics (Nasdaq: TCRX) announced two abstract acceptances for presentation at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. The company will deliver an oral presentation on CD8+ T cell targets in Ankylosing Spondylitis and Birdshot Uveitis, and a poster presentation on HLA Class II-restricted autoantigens in Scleroderma and Ulcerative Colitis.
While primarily focused on oncology, TScan's proprietary TargetScan technology has identified several shared T-cell targets in Ankylosing Spondylitis, representing a potential breakthrough in an area where therapeutic targets have remained elusive. The presentations will showcase the platform's capabilities in identifying novel targets for autoimmune disorders.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 5:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:00 a.m. ET. Both presentations will be available via webcast on the company's investor relations website for 90 days following the events.
TScan Therapeutics (Nasdaq: TCRX) reported Q2 2025 financial results and provided updates on its TCR-T therapy programs. The company reported revenue of $3.1 million and a net loss of $37.0 million. Key developments include plans to dose first solid tumor patients with multiplex TCR-T in Q3 2025 and present two-year relapse data from the ALLOHA™ Phase 1 heme trial by year-end.
The company's cash position stands at $218.0 million, expected to fund operations into Q1 2027. TScan plans to initiate a registrational trial for TSC-101 in H2 2025 and file an IND for TSC-102-A0301. Initial safety and response data from the PLEXI-T trial is expected in Q1 2026.
TScan Therapeutics (NASDAQ: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 4:55 p.m. Eastern Time at the Marriott Marquis in New York. Investors and interested parties can access the presentation webcast through the "Events and Presentations" section on TScan's website at ir.tscan.com, with the replay remaining available for 90 days after the event.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its upcoming presentation at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.
The event will take place from May 13-17 in New Orleans, LA, with both in-person and virtual attendance options. The company will present a poster focused on "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."
- Presentation Date: Tuesday, May 13
- Time: 6:00 - 7:30 p.m. Central Time
- Location: Poster Hall, Hall I2
- Abstract Number: AMA1180
The presentation materials will be made available on TScan's website (tscan.com) in the "Publications" section after the presentation concludes.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for April 7, 2025, at 9:30 a.m. Eastern Time.
Interested parties can access the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com. The replay will remain available for 90 days following the event.
TScan Therapeutics (TCRX) has appointed Stephen Camiolo as Senior Vice President of Market Access, bringing over 25 years of industry experience. Camiolo, who most recently served as Vice President of National Cell Therapy Account Teams at Iovance Biotherapeutics, has led 16 successful product launches, including three cell therapies.
The appointment comes as TScan prepares to launch a pivotal trial of TSC-101 for treating residual disease and preventing relapse in patients with AML, ALL, and MDS later this year. The company continues to advance enrollment in its PLEXI-T™ solid tumor program.
Prior to joining TScan, Camiolo held leadership positions at Iovance, where he led the strategic launch of AMTAGVI®, CRISPR Therapeutics, Gilead Sciences, and Kite Pharma, focusing on market access, pricing strategy, and commercial operations.
TScan Therapeutics (NASDAQ: TCRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its cancer treatment pipeline. The company's ALLOHA™ Phase 1 heme trial showed promising results with only 2 of 26 patients relapsing compared to 4 of 12 in the control arm.
Key financial highlights include: Q4 2024 revenue of $0.7M (down from $7.2M in Q4 2023), full-year revenue of $2.8M (down from $21M in 2023), and a Q4 net loss of $35.8M. The company secured $30M through a registered direct offering at a 37% premium and refinanced its debt with a $52.5M term loan from SVB.
R&D expenses increased to $107.4M for 2024 (from $88.2M in 2023) due to expanded clinical trials. With $290.1M in cash and equivalents, TScan expects to fund operations into Q1 2027. The company plans to initiate a registration trial for TSC-101 in H2 2025 and anticipates presenting multiplex TCR-T therapy data in the second half of 2025.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.
Investors and interested parties can access the presentation through a webcast available on the 'Events and Presentations' section of TScan's website at ir.tscan.com. The webcast recording will remain accessible on the company's website for 90 days after the event.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
